Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors?

Author:

Nakayama Takahiro1ORCID,Fujisawa Fumie2ORCID

Affiliation:

1. Breast & Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan

2. Medical Oncology, Osaka International Cancer Institute, Osaka, Japan

Abstract

Despite advances in the treatment of hormone receptor-positive, HER2- metastatic breast cancer, the disease is rarely curable. In this review, we focus on the use of CDK4/6 inhibitors, examining clinical experience and the mechanisms underlying the development of resistance, and evaluating treatment options after failure to respond to CDK4/6 inhibitors. Current basic research supports the use of mammalian target of rapamycin inhibitors after CDK4/6 inhibitor failure; however, more data are needed, particularly regarding treatment sequencing. Real-world data studies may help to fill the current knowledge gap, particularly where large-scale randomized controlled studies are not feasible.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Reference66 articles.

1. Globocan fact sheet: Japan (2018). http://gco.iarc.fr/today/data/factsheets/populations/392-japan-fact-sheets.pdf

2. Projected cancer statistics (2018). https://ganjoho.jp/en/public/statistics/short_pred.html

3. Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

4. Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable?

5. Japanese Breast Cancer Society. Clinical Practice Guidelines for Breast Cancer Treatment [in Japanese]. Kanehara Shuppan, Tokyo (2018). http://jbcs.gr.jp/guidline/2018/about/

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3